A Decrease in the Dose of Pegvisomant was Needed for the Treatment of Acromegaly after Adrenalectomy in a Patient with Coexisting Preclinical Cushing's Syndrome

DOI Web Site 被引用文献2件 参考文献26件
  • Ogo Atsushi
    Department of Metabolism and Endocrinology, National Hospital Organization, Kyushu Medical Center, Japan
  • Matoba Yuka
    Department of Metabolism and Endocrinology, National Hospital Organization, Kyushu Medical Center, Japan
  • Matsuda Yayoi
    Department of Metabolism and Endocrinology, National Hospital Organization, Kyushu Medical Center, Japan
  • Hiramatsu Shinsuke
    Department of Metabolism and Endocrinology, National Hospital Organization, Kyushu Medical Center, Japan

この論文をさがす

抄録

We herein describe the case of a 47-year-old woman with pre-clinical Cushing's syndrome caused by a left adrenal adenoma, which was diagnosed 6 years after trans-sphenoidal selective removal of a pituitary adenoma for acromegaly at age 35. The patient was started on bromocriptine and then somatostatin analogues after the surgery; however, since her serum insulin-like growth factor-1 (IGF-1) values remained above the age-adjusted normal range, the treatment for acromegaly was switched from somatostatin analogues to pegvisomant (10 mg daily), before a left laparoscopic adrenalectomy. After the subsequent adrenalectomy, the dose of pegvisomant could be reduced gradually to once every 4 days without any increase in the serum IGF-1 values. This is the first report describing the need for a different dose of pegvisomant for the treatment of acromegaly before and after adrenalectomy for pre-clinical Cushing's syndrome.<br>

収録刊行物

  • Internal Medicine

    Internal Medicine 50 (18), 1987-1991, 2011

    一般社団法人 日本内科学会

被引用文献 (2)*注記

もっと見る

参考文献 (26)*注記

もっと見る

キーワード

詳細情報 詳細情報について

問題の指摘

ページトップへ